Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 30, 2006

View Archived Issues

Plasmacytoid DCs regarded as targets for microbicides

Novel dual PPARgamma/delta agonist controls dyslipidemia and hyperglycemia in diabetes

Recent Vernalis patent reports novel analgesic agents

Novel agents for treating neurological disorders disclosed in recent patent literature

Recent patents report novel therapeutic agents for hepatitis C virus infection

New peptidomimetic C5a receptor antagonist displays superior selectivity and in vivo activity

Ingested SIRS effective in preclinical models of type 1 diabetes and EAE

Gabapentin may be effective in treatment of neurogenic overactive bladder

Recent patents describe new treatment strategies for diabetes

Novogen offers overview of year's highlights

Allos completes enrollment in pivotal study of Efaproxyn

MedImmune and Infinity team up to develop small molecule cancer drugs

Colazal receives pediatric exclusivity

Milestones at BioMarin

SGX discontinues phase II/III study of Troxatyl in third-line AML

Enrollment completed in U.S. phase III study of Aridol

Six-week follow-up completed in study of Cethrin in acute spinal cord injury

Sinovac Biotech reports preliminary phase I trial of pandemic influenza vaccine

Nigerian phase III study of Savvy ended early

Rituxan shows benefit in relapsing-remitting MS

Extina shows non-inferiority versus ketoconazole cream in seborrheic dermatitis

Review extended for desvenlafaxine succinate NDA

Gestiva recommended for approval to prevent preterm birth

E.U. approval for Exjade

Advances in anti-HIV microbicides reported at the recent AIDS conference

Resistance to peginterferon/ribavirin conferred by increased expression of interferon genes

ITMN-191 continues preclinical development, clinical trials warranted

Rapamycin shows efficacy against Listeria monocytogenes infection in mice

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...